Longeveron Inc. (LGVN)
| Previous close | 7.52 |
| Open | 7.26 |
| Bid | 7.81 x 1800 |
| Ask | 7.88 x 1000 |
| Day's range | 7.26 - 7.88 |
| 52-week range | 2.84 - 45.00 |
| Volume | |
| Avg. volume | 5,319,611 |
| Market cap | 163.941M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings date | 14 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.17 |
- Simply Wall St.
Multiple insiders bought Longeveron Inc. (NASDAQ:LGVN) stock earlier this year, a positive sign for shareholders
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- GlobeNewswire
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
Conference call scheduled for 8:30 a.m. ET todayMIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter ended March 31, 2022. First Quarter Business Updates: Lomecel-B for Alzheimer’s Disease: In January 2022, we initiated enrollment in a
- GlobeNewswire
Longeveron Announces CEO Transition
-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company") announced today the resignation of Chief Executive Officer (CEO) Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities. Longeveron’s Board of Directors has approved the appo
